Protocol - Spirometry - Adult
- Peak Expiratory Flow Rate (PEFR)
- Personal and Family History of Respiratory Symptoms/Diseases - Adult
- Personal and Family History of Respiratory Symptoms/Diseases - Child
- Respiratory Rate - Adult
- Respiratory Rate - Child
- Respiratory Rate - Infant
Description
A spirometric test requires that the subject take a full, deep breath and then exhale as forcefully as possible into a handheld portable spirometer for several seconds. The subjects effort is called the forced expiratory maneuver and most commonly measures the amount and speed of air that is exhaled. The total amount (volume) of air exhaled is called the forced vital capacity (FVC). The amount of air exhaled in the first second is called the forced expiratory volume in 1 second (FEV1). Although handheld spirometers are commonly used in clinical research studies, the same results can be obtained from more-sophisticated floor-mounted devices, which are typically available in a respiratory function testing laboratory.
Specific Instructions
Numerous instructions are embedded in the protocol and in Table 1 of the protocol. This protocol is mainly for adults. The Spirometry - Preschool and Child protocol uses animated computer software and visual cues, which are necessary for young children.
The Sickle Cell Disease Curative Therapy Working Group recommends that this protocol be performed in transplant patients at one time point pre-transplant (baseline) and 100 days, six months, and annually post-hematopoietic cell transplant (HCT). The Working Group notes that a reduction in forced expiratory volume in 1 second (FEV1) can be caused by chronic graft versus host disease (GvHD) of the lungs.
Availability
Protocol
The following description summarizes some of the key points. For the full protocol, see Miller et al., 2005.
Equipment
Spirometers usually come with computer software. The spirometer must be connected to a computer during the spirometry tests. Provide subjects with a mouthpiece and a noseclip. Use of a noseclip is highly recommended but not mandatory. Allow subjects to put the mouthpiece in their mouth and blow with the noseclip attached to their nose. Record whether the noseclip was used.
Quality control
To calibrate the spirometer, attach the device to a 3 liter syringe. Attach the spirometer to a computer and open the spirometry software to calibrate the spirometer. This calibration will measure the flow rate of the spirometer. Conduct three tests with the syringe and ensure that each result is ± 3% of the other tests. This is called a calibration check. Similarly, the syringe must also be calibrated; generally, the syringe flow rate results should be ± 0.5% of the other tests. Perform quality control tests on a weekly basis (see the manufacturer recommendations) and record the results in a log.
Demonstration
Provide a brief explanation of the spirometry test. Do multiple demonstrations of the spirometry test for each subject. Allow subjects to do practice attempts by putting their mouths on the spirometer, inhaling fully, and exhaling as forcefully as possible until no more air can be expelled. It may be useful to refer to the exhalation as a “blast” to ensure subjects exhale as forcefully as possible.
Setting
The subject should be sitting in a chair. Record the position (sitting or standing).
Successful maneuvers
After the subject blows into the spirometer, the technician determines whether the attempt was a successful “maneuver.” An adequate spirometry test requires a minimum of three acceptable maneuvers (see the full protocol for more details about successful maneuvers).
Recorded results
Record the following results.
- Forced Vital Capacity (FVC)
- Forced Expiratory Volume in 0.5 seconds (FEV.5)
- Forced Expiratory Volume in 0.75 seconds (FEV.75)
- Forced Expiratory Volume in 1 second (FEV1)
- Repeatability of parameters above (see repeatability maneuver criteria in full protocol)
- Number of satisfactory attempts (maneuvers)
- Posture (sitting/standing)
Nose clips (yes/no)
Personnel and Training Required
Technician trained in conducting Pulmonary Function Tests (PFTs) with a spirometer
Equipment Needs
The primary instrument used in pulmonary function testing is the spirometer.
Requirements
Requirement Category | Required |
---|---|
Major equipment | No |
Specialized training | Yes |
Specialized requirements for biospecimen collection | No |
Average time of greater than 15 minutes in an unaffected individual | No |
Mode of Administration
Physical Examination
Lifestage
Adolescent, Adult
Participants
Adults
Selection Rationale
Spirometry is invaluable as a screening test of general respiratory health. This protocol is the international standard supported by both the American Thoracic Society and the European Respiratory Society. The selected protocol is well-established over many years and serves as the unambiguous standard for lung function assessment in clinical research studies.
Language
Chinese, English
Standards
Standard | Name | ID | Source |
---|---|---|---|
Logical Observation Identifiers Names and Codes (LOINC) | Resp spirometry proto | 62639-0 | LOINC |
caDSR Form | PhenX PX091601 - Spirometry | 5970262 | caDSR Form |
Derived Variables
None
Process and Review
Expert Review Panel #6 (ERP 6) reviewed the measures in the Respiratory domain.
Guidance from the ERP 6 includes the following:
• No significant changes to measure
Back-compatible: no changes to the Data Dictionary
Previous version in Toolkit archive (link)
Protocol Name from Source
Miller, M. R., et al, Standardization of spirometry. Series “ATS/ERS task force: Standardization of lung function testing.”, EUR RESPIR J, 2005
Source
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., . . . Wanger, J. (2005). Standardisation of spirometry. Series “ATS/ERS task force: Standardisation of lung function testing.” European Respiratory Journal, 26(2), 330-331.
General References
Andreeva, E., Pokhaznikova, M., Lebedev, A., Moiseeva, I., Kozlov, A., Kuznetsova, O., & Degryse, J. (2015). The RESPECT study: RESearch on the PrEvalence and the diagnosis of COPD and its Tobacco-related etiology: a study protocol. BMC Public Health, 15(1), 831.
Berntsen, S., Stølevik, S. B., Mowinckel, P., Nystad, W., & Stensrud, T. (2016). Lung function monitoring; A randomized agreement study. Open Respiratory Medicine Journal, 10, 51-57.
Centers for Disease Control and Prevention (CDC). National Health and Nutrition Examination Survey (NHANES) 2007-2008. Respiratory Health Spirometry Procedures Manual.
Protocol ID
91601
Variables
Export VariablesVariable Name | Variable ID | Variable Description | dbGaP Mapping | |
---|---|---|---|---|
PX091601_Acceptable_Maneuver | ||||
PX091601120000 | Acceptable manoeuvre | Variable Mapping | ||
PX091601_Age | ||||
PX091601360000 | Age | Variable Mapping | ||
PX091601_Barometric_Pressure | ||||
PX091601040000 | Barometric pressure | Variable Mapping | ||
PX091601_Blank10 | ||||
PX091601730000 | Blank 10 | N/A | ||
PX091601_Blank1_Or_FEF25 | ||||
PX091601640000 | Blank 1 or FEF25% | Variable Mapping | ||
PX091601_Blank2_Or_FEF50 | ||||
PX091601650000 | Blank 2 or FEF50% | Variable Mapping | ||
PX091601_Blank3_Or_FEF75 | ||||
PX091601660000 | Blank 3 or FEF75% | Variable Mapping | ||
PX091601_Blank4_Or_FEF90 | ||||
PX091601670000 | Blank 4 or FEF90% | N/A | ||
PX091601_Blank5 | ||||
PX091601680000 | Blank 5 | N/A | ||
PX091601_Blank6 | ||||
PX091601690000 | Blank 6 | N/A | ||
PX091601_Blank7 | ||||
PX091601700000 | Blank 7 | N/A | ||
PX091601_Blank8 | ||||
PX091601710000 | Blank 8 | N/A | ||
PX091601_Blank9 | ||||
PX091601720000 | Blank 9 | N/A | ||
PX091601_BTPS_Calculation_Temperature | ||||
PX091601050000 | Temperature (ºC) used in BTPS calculation | N/A | ||
PX091601_BTPS_Factor | ||||
PX091601190000 | BTPS factor | Variable Mapping | ||
PX091601_Calibration_Date | ||||
PX091601290000 | Calibration date | N/A | ||
PX091601_Calibration_Result | ||||
PX091601310000 | Calibration result | Variable Mapping | ||
PX091601_Calibration_Time | ||||
PX091601300000 | Calibration time | Variable Mapping | ||
PX091601_City | ||||
PX091601230000 | City | N/A | ||
PX091601_Comments_Text | ||||
PX091601620000 | Comments text | Variable Mapping | ||
PX091601_Computer_Quality | ||||
PX091601140000 | Computer quality code | Variable Mapping | ||
PX091601_Country | ||||
PX091601260000 | Country | N/A | ||
PX091601_Data_Type | ||||
PX091601030000 | Data type | N/A | ||
PX091601_Date | ||||
PX091601320000 | Date | N/A | ||
PX091601_Date_Of_Birth | ||||
PX091601410000 | Date of birth | Variable Mapping | ||
PX091601_Date_Of_Review | ||||
PX091601170000 | Date of review | N/A | ||
PX091601_Deleted_Maneuver | ||||
PX091601110000 | Deleted manoeuvre | Variable Mapping | ||
PX091601_Effort_Attribute | ||||
PX091601090000 | Effort attribute | N/A | ||
PX091601_Email | ||||
PX091601270000 | N/A | |||
PX091601_Extrapolated_Volume | ||||
PX091601490000 | Extrapolated volume | Variable Mapping | ||
PX091601_FES_25_75 | ||||
PX091601530000 | FEF25-75% | Variable Mapping | ||
PX091601_FEV1 | ||||
PX091601500000 | FEV1 | Variable Mapping | ||
PX091601_FEV1_Quality | ||||
PX091601080000 | FEV1 quality attribute | Variable Mapping | ||
PX091601_FEV6 | ||||
PX091601510000 | FEV6 | Variable Mapping | ||
PX091601_Flow_Data_Points | ||||
PX091601750000 | Flow data points (mL/s; variable number more
contained in number of data points) show less
|
N/A | ||
PX091601_Forced_Expiratory_Time | ||||
PX091601550000 | Forced expiratory time | Variable Mapping | ||
PX091601_FVC | ||||
PX091601480000 | FVC | Variable Mapping | ||
PX091601_FVC_Quality | ||||
PX091601070000 | FVC quality attribute | Variable Mapping | ||
PX091601_Height | ||||
PX091601370000 | Height | Variable Mapping | ||
PX091601_Maneuver_Number | ||||
PX091601350000 | Manoeuvre number | N/A | ||
PX091601_Methacholine_Concentration | ||||
PX091601460000 | Methacholine Concentration | N/A | ||
PX091601_Methacholine_Dose | ||||
PX091601470000 | Methacholine dose | N/A | ||
PX091601_Number_Of_Data_Points | ||||
PX091601740000 | Number of data points | N/A | ||
PX091601_Original_Sampling_Interval | ||||
PX091601630000 | Original sampling interval | N/A | ||
PX091601_PEF | ||||
PX091601520000 | PEF | Variable Mapping | ||
PX091601_Phone_Number | ||||
PX091601280000 | Phone number | N/A | ||
PX091601_Plateau | ||||
PX091601150000 | Plateau achieved | Variable Mapping | ||
PX091601_Predicted_FEV1 | ||||
PX091601580000 | Predicted FEV1 | Variable Mapping | ||
PX091601_Predicted_FEV1/FEV6 | ||||
PX091601610000 | Predicted FEV1/FEV6% | Variable Mapping | ||
PX091601_Predicted_FEV1/FVC | ||||
PX091601600000 | Predicted FEV1/FVC% | Variable Mapping | ||
PX091601_Predicted_FEV6 | ||||
PX091601590000 | Predicted FEV6 | N/A | ||
PX091601_Predicted_FVC | ||||
PX091601570000 | Predicted FVC | Variable Mapping | ||
PX091601_Race | ||||
PX091601400000 | Race (2-character race code) | Variable Mapping | ||
PX091601_Reference_Value_Correction | ||||
PX091601430000 | Reference values correction factor | N/A | ||
PX091601_Reference_Value_Source | ||||
PX091601420000 | Reference values source (first author more
surname and date of publication, e.g.''Knudson 1983'') show less
|
N/A | ||
PX091601_Relative_Humidity | ||||
PX091601060000 | Relative humidity (%) | N/A | ||
PX091601_Review | ||||
PX091601160000 | Review | N/A | ||
PX091601_Reviewer_Initials | ||||
PX091601180000 | Reviewer initials | N/A | ||
PX091601_Sex | ||||
PX091601390000 | Sex | Variable Mapping | ||
PX091601_Spirometer_Manufacturer | ||||
PX091601200100 | Spirometer manufacturer | N/A | ||
PX091601_Spirometer_Model | ||||
PX091601200200 | Spirometer model | N/A | ||
PX091601_Spirometer_Serial_Number | ||||
PX091601200300 | Spirometer serial number | N/A | ||
PX091601_Spirometer_Type | ||||
PX091601210000 | Spirometer type | N/A | ||
PX091601_State_Region | ||||
PX091601240000 | State/region | N/A | ||
PX091601_Technician_ID | ||||
PX091601340000 | Technician ID | Variable Mapping | ||
PX091601_Technician_Quality | ||||
PX091601130000 | Technician quality control code | Variable Mapping | ||
PX091601_Testing_Facility | ||||
PX091601220000 | Testing facility name | N/A | ||
PX091601_Testing_Position | ||||
PX091601440000 | Testing position | Variable Mapping | ||
PX091601_Test_Type | ||||
PX091601450000 | Test type | N/A | ||
PX091601_Time | ||||
PX091601330000 | Time | Variable Mapping | ||
PX091601_Time_To_PEF | ||||
PX091601560000 | Time to PEF | Variable Mapping | ||
PX091601_VC | ||||
PX091601540000 | VC | Variable Mapping | ||
PX091601_Weight | ||||
PX091601380000 | Weight | Variable Mapping | ||
PX091601_Zip_Code | ||||
PX091601250000 | Zip/post code | N/A |
Measure Name
Spirometry
Release Date
January 29, 2010
Definition
Spirometry is a common pulmonary function test (PFT) measuring the amount (volume) and/or speed (flow) of air being inhaled and exhaled.
Purpose
Spirometry is a tool used to screen for the presence of obstructive and restrictive lung diseases.
Keywords
Respiratory, pulmonary function test, PFT, American Thoracic Society, ATS, European Respiratory Society, ERS, forced vital capacity, FVC, forced expiratory volume, FEV
Measure Protocols
Protocol ID | Protocol Name |
---|---|
91601 | Spirometry - Adult |
91602 | Spirometry - Child |
Publications
Ross, J. M., et al. (2022) The effects of cannabis use on physical health: A co-twin control study. Drug and Alcohol Dependence. 2022 January; 230: 109200. doi: 10.1016/j.drugalcdep.2021.109200
Mapped dbGaP Studies
Mapping for PX091601_Acceptable_Maneuver
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083488 | COMPLETED SPIROMETRY MANEUVER |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083723 | COMPLETED SPIROMETRY MANEUVER |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087714 | COMPLETED SPIROMETRY MANEUVER |
Mapped dbGaP Studies
Mapping for PX091601_Age
Mapped dbGaP Studies
Mapping for PX091601_Barometric_Pressure
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
CARDIA Cohort | phv00113392 | BAROMETRIC PRESSURE (740-780 MM HG) |
CARDIA Cohort | phv00114606 | BAROMETRIC PRESSURE |
CARDIA Cohort | phv00115701 | BAROMETRIC PRESSURE |
CARDIA Cohort | phv00118955 | BAROMETRIC PRESSURE |
Framingham Cohort | phv00022583 | BAROMETRIC PRESSURE IN CENTIMETERS |
Mapped dbGaP Studies
Mapping for PX091601_Blank1_Or_FEF25
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Atherosclerosis Risk in Communities (ARIC) Cohort | phv00095667 | FEF(25) Q35 |
Atherosclerosis Risk in Communities (ARIC) Cohort | phv00095620 | FEF(25) |
CARDIA Cohort | phv00118965 | FEF AT 25% FROM MAX CURVE (8 TRIALS) |
CARDIA Cohort | phv00118936 | FEF AT 25% FROM MAX CURVE (5 TRIALS) |
CARDIA Cohort | phv00115682 | FEF AT 25% FROM MAX CURVE |
CARDIA Cohort | phv00114689 | FEF AT 25% FROM MAX CURVE |
Framingham Cohort | phv00073839 | Forced expiratory flow at 25% of FVC - best effort |
Framingham Cohort | phv00196593 | Forced Expiratory Flow (FEF) at 25% of Forced Vital Capacity (FVC), (FEF25) - Best Effort, Albuterol |
Framingham Cohort | phv00196576 | Forced Expiratory Flow (FEF) at 25% of Forced Vital Capacity (FVC), (FEF25) - Best Effort, Albuterol |
Framingham Cohort | phv00196559 | Forced Expiratory Flow (FEF) at 25% of Forced Vital Capacity (FVC), (FEF25) - Best Effort |
Framingham Cohort | phv00002688 | LUNG FUNCTION: FEF (25) |
Framingham Cohort | phv00022695 | FORCED EXPIRATORY FLOW AT 25% OF FVC (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022684 | FORCED EXPIRATORY FLOW AT 25% OF FVC (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022670 | FORCED EXPIRATORY FLOW AT 25% OF FVC (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022659 | FORCED EXPIRATORY FLOW AFTER 25% OF THE FVC HAS BEEN EXPIRED - SUMMARY |
Framingham Cohort | phv00022644 | FORCED EXPIRATORY FLOW AFTER 25% OF THE FVC HAS BEEN EXPIRED - TRIAL 5 |
Framingham Cohort | phv00022631 | FORCED EXPIRATORY FLOW AFTER 25% OF THE FVC HAS BEEN EXPIRED - TRIAL 4 |
Framingham Cohort | phv00022618 | FORCED EXPIRATORY FLOW AFTER 25% OF THE FVC HAS BEEN EXPIRED - TRIAL 3 |
Framingham Cohort | phv00022605 | FORCED EXPIRATORY FLOW AFTER 25% OF THE FVC HAS BEEN EXPIRED - TRIAL 1 |
Framingham Cohort | phv00022592 | FORCED EXPIRATORY FLOW AFTER 25% OF THE FVC HAS BEEN EXPIRED - TRIAL 1 |
Framingham Cohort | phv00022576 | FORCED EXPIRATORY FLOW AT 25% OF FVC (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022561 | FORCED EXPIRATORY FLOW AT 25% OF FVC (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00003255 | LUNG FUNCTION: FEF (25) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083455 | FORCED EXPIRATORY FLOW 25% (ml/sec) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083690 | FORCED EXPIRATORY FLOW 25% (ml/sec) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087681 | FORCED EXPIRATORY FLOW 25% (ml/sec) |
NHLBI Cleveland Family Study (CFS) Candidate Gene Association Resource (CARe) | phv00122581 | Spirometry: forced expiratory flow at 25 |
Mapped dbGaP Studies
Mapping for PX091601_Blank2_Or_FEF50
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Atherosclerosis Risk in Communities (ARIC) Cohort | phv00095668 | FEF(50) Q36 |
Atherosclerosis Risk in Communities (ARIC) Cohort | phv00095621 | FEF(50) |
CARDIA Cohort | phv00118966 | FEF AT 50% FROM MAX CURVE (8 TRIALS) |
CARDIA Cohort | phv00118937 | FEF AT 50% FROM MAX CURVE (5 TRIALS) |
CARDIA Cohort | phv00115683 | FEF AT 50% FROM MAX CURVE |
CARDIA Cohort | phv00114690 | FEF AT 50% FROM MAX CURVE |
Framingham Cohort | phv00003256 | LUNG FUNCTION: FEF (50) |
Framingham Cohort | phv00196594 | Forced Expiratory Flow (FEF) at 50% of Forced Vital Capacity (FVC), (FEF50) - Best Effort, Albuterol |
Framingham Cohort | phv00196577 | Forced Expiratory Flow (FEF) at 50% of Forced Vital Capacity (FVC), (FEF50) - Best Effort, Albuterol |
Framingham Cohort | phv00196560 | Forced Expiratory Flow (FEF) at 50% of Forced Vital Capacity (FVC), (FEF50) - Best Effort |
Framingham Cohort | phv00073840 | Forced expiratory flow at 50% of FVC - best effort |
Framingham Cohort | phv00022696 | FORCED EXPIRATORY FLOW AT 50% OF FVC (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022606 | FORCED EXPIRATORY FLOW AFTER 50% OF THE FEV HAS BEEN EXPIRED - TRIAL 2 |
Framingham Cohort | phv00002689 | LUNG FUNCTION: FEF (50) |
Framingham Cohort | phv00022562 | FORCED EXPIRATORY FLOW AT 50% OF FVC (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022577 | FORCED EXPIRATORY FLOW AT 50% OF FVC (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022593 | FORCED EXPIRATORY FLOW AFTER 50% OF THE FEV HAS BEEN EXPIRED - TRIAL 1 |
Framingham Cohort | phv00022685 | FORCED EXPIRATORY FLOW AT 50% OF FVC (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022619 | FORCED EXPIRATORY FLOW AFTER 50% OF THE FEV HAS BEEN EXPIRED - TRIAL 3 |
Framingham Cohort | phv00022632 | FORCED EXPIRATORY FLOW AFTER 50% OF THE FEV HAS BEEN EXPIRED - TRIAL 4 |
Framingham Cohort | phv00022645 | FORCED EXPIRATORY FLOW AFTER 50% OF THE FEV HAS BEEN EXPIRED - TRIAL 5 |
Framingham Cohort | phv00022660 | FORCED EXPIRATORY FLOW AFTER 50% OF THE FEV HAS BEEN EXPIRED - SUMMARY |
Framingham Cohort | phv00022671 | FORCED EXPIRATORY FLOW AT 50% OF FVC (LIT./SEC.) - BEST EFFORT |
Jackson Heart Study (JHS) Cohort | phv00128218 | BEST_FEF50 - FEF 50: Flow at 50% of FVC from best curve |
Jackson Heart Study (JHS) Cohort | phv00128228 | SCND_FEF50 - FEF 50: Flow at 50% of FVC from 2nd best curve |
Jackson Heart Study (JHS) Cohort | phv00128238 | THRD_FEF50 - FEF 50: Flow at 50% of FVC from 3rd best curve |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087682 | FORCED EXPIRATORY FLOW 50% (ml/sec) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083691 | FORCED EXPIRATORY FLOW 50% (ml/sec) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083456 | FORCED EXPIRATORY FLOW 50% (ml/sec) |
NHLBI Cleveland Family Study (CFS) Candidate Gene Association Resource (CARe) | phv00122582 | Spirometry: forced expiratory flow at 50 |
Mapped dbGaP Studies
Mapping for PX091601_Blank3_Or_FEF75
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Atherosclerosis Risk in Communities (ARIC) Cohort | phv00095964 | FEF(75) Predicted |
Atherosclerosis Risk in Communities (ARIC) Cohort | phv00095955 | FEF(75) Predicted |
Atherosclerosis Risk in Communities (ARIC) Cohort | phv00095669 | FEF(75) Q37 |
Atherosclerosis Risk in Communities (ARIC) Cohort | phv00095622 | FEF(75) |
CARDIA Cohort | phv00118967 | FEF AT 75% FROM MAX CURVE (8 TRIALS) |
CARDIA Cohort | phv00118938 | FEF AT 75% FROM MAX CURVE (5 TRIALS) |
CARDIA Cohort | phv00115684 | FEF AT 75% FROM MAX CURVE |
CARDIA Cohort | phv00114691 | FEF AT 75% FROM MAX CURVE |
Framingham Cohort | phv00003257 | LUNG FUNCTION: FEF (75) |
Framingham Cohort | phv00196595 | Forced Expiratory Flow (FEF) at 75% of Forced Vital Capacity (FVC), (FEF75) - Best Effort, Albuterol |
Framingham Cohort | phv00196578 | Forced Expiratory Flow (FEF) at 75% of Forced Vital Capacity (FVC), (FEF75) - Best Effort, Albuterol |
Framingham Cohort | phv00196561 | Forced Expiratory Flow (FEF) at 75% of Forced Vital Capacity (FVC), (FEF75) - Best Effort |
Framingham Cohort | phv00073841 | Forced expiratory flow at 75% of FVC - best effort |
Framingham Cohort | phv00022697 | FORCED EXPIRATORY FLOW AT 75% OF FVC (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022686 | FORCED EXPIRATORY FLOW AT 75% OF FVC (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022672 | FORCED EXPIRATORY FLOW AT 75% OF FVC (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022661 | FORCED EXPIRATORY FLOW AFTER 75% OF THE FEV HAS BEEN EXPIRED - SUMMARY |
Framingham Cohort | phv00022646 | FORCED EXPIRATORY FLOW AFTER 75% OF THE FEV HAS BEEN EXPIRED - TRIAL 5 |
Framingham Cohort | phv00022633 | FORCED EXPIRATORY FLOW AFTER 75% OF THE FEV HAS BEEN EXPIRED - TRIAL 4 |
Framingham Cohort | phv00022620 | FORCED EXPIRATORY FLOW AFTER 75% OF THE FEV HAS BEEN EXPIRED - TRIAL 3 |
Framingham Cohort | phv00022607 | FORCED EXPIRATORY FLOW AFTER 75% OF THE FEV HAS BEEN EXPIRED - TRIAL 2 |
Framingham Cohort | phv00022594 | FORCED EXPIRATORY FLOW AFTER 75% OF THE FEV HAS BEEN EXPIRED - TRIAL 1 |
Framingham Cohort | phv00022578 | FORCED EXPIRATORY FLOW AT 75% OF FVC (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022563 | FORCED EXPIRATORY FLOW AT 75% OF FVC (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00002690 | LUNG FUNCTION: FEF (75) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083457 | FORCED EXPIRATORY FLOW 75% (ml/sec) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083692 | FORCED EXPIRATORY FLOW 75% (ml/sec) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087683 | FORCED EXPIRATORY FLOW 75% (ml/sec) |
NHLBI Cleveland Family Study (CFS) Candidate Gene Association Resource (CARe) | phv00122583 | Spirometry: forced expiratory flow at 75 |
Mapped dbGaP Studies
Mapping for PX091601_BTPS_Factor
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083449 | BTPS FACTOR |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083684 | BTPS FACTOR |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087675 | BTPS FACTOR |
Mapped dbGaP Studies
Mapping for PX091601_Calibration_Result
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083451 | CALIBRATION CODE |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083686 | CALIBRATION CODE |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087677 | CALIBRATION CODE |
Mapped dbGaP Studies
Mapping for PX091601_Calibration_Time
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083450 | CALIBRATION TIME |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083685 | CALIBRATION TIME |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087676 | CALIBRATION TIME |
Mapped dbGaP Studies
Mapping for PX091601_Comments_Text
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00175852 | LAA COMMENT |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00175853 | EXTRA COMMENT |
NHGRI Tumor Sequencing Project (Lung Adenocarcinoma) | phv00071776 | Comment on WGA QA failure |
Mapped dbGaP Studies
Mapping for PX091601_Computer_Quality
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Jackson Heart Study (JHS) Cohort | phv00128203 | Computer QC (Flow) - Quality Control Score assigned by computer for flow aspects of curve |
Jackson Heart Study (JHS) Cohort | phv00128204 | Computer QC (Volume) - Quality Control Score assigned by computer for volume aspects |
Mapped dbGaP Studies
Mapping for PX091601_Date_Of_Birth
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
CARDIA Cohort | phv00113717 | BIRTHDATE (VERIFIED AT EXAM 2) |
CARDIA Cohort | phv00115116 | BIRTHDATE (VERIFIED AT EXAM 2) |
CARDIA Cohort | phv00116381 | BIRTHDATE (VERIFIED AT EXAM 2) |
CARDIA Cohort | phv00116483 | PATIENT DATA: DATE OF BIRTH |
CARDIA Cohort | phv00117582 | BIRTHDATE (VERIFIED AT EXAM 2) |
CARDIA Cohort | phv00119625 | BIRTHDATE (VERIFIED AT PPTS LAST EXAM) |
CARDIA Cohort | phv00120736 | BIRTHDATE (VERIFIED AT PPTS LAST EXAM) |
DCCT-EDIC Clinical Trial and Follow-up of Persons with Type 1 Diabetes | phv00032010 | Date of birth |
Diet, Genetic Factors, and the Gut Microbiome in Crohn's Disease | phv00090690 | Date of birth |
Genetic Multiple Sclerosis Associations - GeneMSA | phv00073000 | Birth date |
Jackson Heart Study (JHS) Cohort | phv00125920 | CARe PARTICIPANT DATE OF BIRTH YEAR |
Mapped dbGaP Studies
Mapping for PX091601_Deleted_Maneuver
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083446 | INDICATOR THAT THE MANEUVER WAS DELETED DUE TO POOR QUALITY |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083681 | INDICATOR THAT THE MANEUVER WAS DELETED DUE TO POOR QUALITY |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087672 | INDICATOR THAT THE MANEUVER WAS DELETED DUE TO POOR QUALITY |
Mapped dbGaP Studies
Mapping for PX091601_Extrapolated_Volume
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083454 | EXTRAPOLATED VOLUME (ml) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083689 | EXTRAPOLATED VOLUME (ml) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087680 | EXTRAPOLATED VOLUME (ml) |
Mapped dbGaP Studies
Mapping for PX091601_FES_25_75
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Atherosclerosis Risk in Communities (ARIC) Cohort | phv00095670 | FEF(25-75) Q38 |
Atherosclerosis Risk in Communities (ARIC) Cohort | phv00095623 | FEF(25-75) |
Framingham Cohort | phv00003254 | LUNG FUNCTION: FEF (25-75) |
Framingham Cohort | phv00196592 | Maximum Mid Expiratory Flow Rate (FEF25-75) - Best Effort, Albuterol |
Framingham Cohort | phv00196558 | Maximum Mid Expiratory Flow Rate (FEF25-75) - Best Effort |
Framingham Cohort | phv00073838 | Maximum mid expiratory flow rate - best effort |
Framingham Cohort | phv00022692 | MAXIMUM MID EXPIRATORY FLOW RATE (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022683 | MAXIMUM MID EXPIRATORY FLOW RATE (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022667 | MAXIMUM MID EXPIRATORY FLOW RATE (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022591 | MAXIMUM MID EXPIRATORY FLOW RATE - TRIAL 1 (AVERAGE RATE OF FLOW DURING MIDDLE HALF OF AN FEV - IN MILLILITERS EXPIRED PER SECOND) |
Framingham Cohort | phv00002687 | LUNG FUNCTION: FEF (25-75) |
Framingham Cohort | phv00022558 | MAXIMUM MID EXPIRATORY FLOW RATE (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022575 | MAXIMUM MID EXPIRATORY FLOW RATE (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022658 | MAXIMUM MID EXPIRATORY FLOW RATE - SUMMARY (AVERAGE RATE OF FLOW DURING MIDDLE HALF OF AN FEV - IN MILLILITERS EXPIRED PER SECOND) |
Framingham Cohort | phv00022604 | MAXIMUM MID EXPIRATORY FLOW RATE - TRIAL 1 (AVERAGE RATE OF FLOW DURING MIDDLE HALF OF AN FEV - IN MILLILITERS EXPIRED PER SECOND) |
Framingham Cohort | phv00022617 | MAXIMUM MID EXPIRATORY FLOW RATE - TRIAL 3 (AVERAGE RATE OF FLOW DURING MIDDLE HALF OF AN FEV - IN MILLILITERS EXPIRED PER SECOND) |
Framingham Cohort | phv00022630 | MAXIMUM MID EXPIRATORY FLOW RATE - TRIAL 4 (AVERAGE RATE OF FLOW DURING MIDDLE HALF OF AN FEV - IN MILLILITERS EXPIRED PER SECOND) |
Framingham Cohort | phv00022643 | MAXIMUM MID EXPIRATORY FLOW RATE - TRIAL 5 (AVERAGE RATE OF FLOW DURING MIDDLE HALF OF AN FEV - IN MILLILITERS EXPIRED PER SECOND) |
Genetic Epidemiology of COPD (COPDGene) | phv00169394 | FEF 25-75 post-bronch |
Genetic Epidemiology of COPD (COPDGene) | phv00169397 | FEF 25-75 pre-bronch |
Genome-Wide Association Study of Serum YKL-40 Levels | phv00066571 | Forced expiratory flow between 25% and 75% of the forced vital capacity (FVC) |
Jackson Heart Study (JHS) Cohort | phv00128212 | BEST_2575 - FEF 25-75 (mid flow) from the best curve: measured in liters |
Jackson Heart Study (JHS) Cohort | phv00128222 | SCND_2575 - FEF 25-75 (mid flow) from the 2nd best curve: measured in |
Jackson Heart Study (JHS) Cohort | phv00128232 | THRD_2575 - FEF 25-75 (mid flow) from the 3rd best curve: measured in liters |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083478 | FORCED EXPIRATORY FLOW 25% TO 75% (ml/sec) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083713 | FORCED EXPIRATORY FLOW 25% TO 75% (ml/sec) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087704 | FORCED EXPIRATORY FLOW 25% TO 75% (ml/sec) |
Mapped dbGaP Studies
Mapping for PX091601_FEV1
Mapped dbGaP Studies
Mapping for PX091601_FEV1_Quality
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Jackson Heart Study (JHS) Cohort | phv00128207 | Reader QC (FEV1) - Pulmonary reading center reader quality score for FEV 1.0 |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083443 | FEV1 QUALITY ASSURANCE GRADE |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083469 | FEV1 QUALITY ASSURANCE GRADE: NUMERIC |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083678 | FEV1 QUALITY ASSURANCE GRADE |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083704 | FEV1 QUALITY ASSURANCE GRADE: NUMERIC |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087669 | FEV1 QUALITY ASSURANCE GRADE |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087695 | FEV1 QUALITY ASSURANCE GRADE: NUMERIC |
Mapped dbGaP Studies
Mapping for PX091601_FEV6
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Atherosclerosis Risk in Communities (ARIC) Cohort | phv00095614 | FEV(6) (liters) |
Atherosclerosis Risk in Communities (ARIC) Cohort | phv00095661 | FEV(6) (liters) Q28 |
Framingham Cohort | phv00196551 | Forced Expiratory Volume at 6 second (FEV6) - Highest value among acceptable maneuvers |
Framingham Cohort | phv00196568 | Forced Expiratory Volume at 6 second (FEV6) - Highest value among acceptable maneuvers, Albuterol |
Framingham Cohort | phv00196585 | Forced Expiratory Volume at 6 second (FEV6) - Highest value among acceptable maneuvers, Albuterol |
Genetic Epidemiology of COPD (COPDGene) | phv00169395 | FEV6 pre-bronch |
Jackson Heart Study (JHS) Cohort | phv00128216 | BEST_FEV6 - Forced expiratory volume in 6 seconds, FEV6.0, from best |
Jackson Heart Study (JHS) Cohort | phv00128226 | SCND_FEV6 - Forced expiratory volume in 6 seconds, FEV6.0, from 2nd best curve; measured in liters |
Jackson Heart Study (JHS) Cohort | phv00128236 | THRD_FEV6 - Forced expiratory volume in 6 seconds, FEV6.0, from 3rd best curve: measured in liters |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083460 | LOWER LIMIT OF NORMAL: FEV6 (ml/sec) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083695 | LOWER LIMIT OF NORMAL: FEV6 (ml/sec) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087686 | LOWER LIMIT OF NORMAL: FEV6 (ml/sec) |
Mapped dbGaP Studies
Mapping for PX091601_Forced_Expiratory_Time
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Framingham Cohort | phv00022559 | FORCED EXPIRATORY TIME (SECONDS) - BEST EFFORT |
Framingham Cohort | phv00022573 | FORCED EXPIRATORY TIME (SECONDS) - BEST EFFORT |
Framingham Cohort | phv00022668 | FORCED EXPIRATORY TIME (SECONDS) - BEST EFFORT |
Framingham Cohort | phv00022693 | FORCED EXPIRATORY TIME (SECONDS) - BEST EFFORT |
Framingham Cohort | phv00073834 | Forced expiratory time |
Framingham Cohort | phv00196554 | Forced Expiratory Time - Highest FVC value among acceptable maneuvers |
Framingham Cohort | phv00196571 | Forced Expiratory Time - Highest FVC value among acceptable maneuvers, Albuterol |
Framingham Cohort | phv00196588 | Forced Expiratory Time - Highest FVC value among acceptable maneuvers, Albuterol |
Mapped dbGaP Studies
Mapping for PX091601_FVC
Mapped dbGaP Studies
Mapping for PX091601_FVC_Quality
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Jackson Heart Study (JHS) Cohort | phv00128206 | Reader QC (FVC) - Pulmonary reading center reader quality score for forced vital capacity |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083442 | FVC QUALITY ASSURANCE GRADE |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083470 | FVC QUALITY ASSURANCE GRADE: NUMERIC |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083677 | FVC QUALITY ASSURANCE GRADE |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083705 | FVC QUALITY ASSURANCE GRADE: NUMERIC |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087668 | FVC QUALITY ASSURANCE GRADE |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087696 | FVC QUALITY ASSURANCE GRADE: NUMERIC |
Mapped dbGaP Studies
Mapping for PX091601_Height
Mapped dbGaP Studies
Mapping for PX091601_PEF
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
CARDIA Cohort | phv00115680 | PEAK EXPIRATORY FLOW RATE FR MAX CURVE |
CARDIA Cohort | phv00114687 | PEAK EXPIRATORY FLOW RATE FR MAX CURVE |
Cardiovascular Health Study (CHS) Cohort | phv00110372 | Best PEF |
Cardiovascular Health Study (CHS) Cohort | phv00110368 | Predicted PEF |
Framingham Cohort | phv00022572 | PEAK EXPIRATORY FLOW (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00196587 | Peak Expiratory Flow (FEFMAX) - Highest value among acceptable maneuvers, Albuterol |
Framingham Cohort | phv00196570 | Peak Expiratory Flow (FEFMAX) - Highest value among acceptable maneuvers, Albuterol |
Framingham Cohort | phv00196553 | Peak Expiratory Flow (FEFMAX) - Highest value among acceptable maneuvers |
Framingham Cohort | phv00073833 | Peak expiratory flow - best effort |
Framingham Cohort | phv00022691 | PEAK EXPIRATORY FLOW (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022666 | PEAK EXPIRATORY FLOW (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022557 | PEAK EXPIRATORY FLOW (LIT./SEC.) - BEST EFFORT |
Framingham Cohort | phv00022590 | PEAK EXPIRATORY FLOW RATE - TRIAL 1 (MAXIMUM RATE OF FLOW ATTAINABLE AT ANY TIME DURING AN FEV) |
Framingham Cohort | phv00022603 | PEAK EXPIRATORY FLOW RATE - TRIAL 1 (MAXIMUM RATE OF FLOW ATTAINABLE AT ANY TIME DURING AN FEV) |
Framingham Cohort | phv00022616 | PEAK EXPIRATORY FLOW RATE - TRIAL 3 (MAXIMUM RATE OF FLOW ATTAINABLE AT ANY TIME DURING AN FEV) |
Framingham Cohort | phv00022629 | PEAK EXPIRATORY FLOW RATE - TRIAL 4 (MAXIMUM RATE OF FLOW ATTAINABLE AT ANY TIME DURING AN FEV) |
Framingham Cohort | phv00022642 | PEAK EXPIRATORY FLOW RATE - TRIAL 5 (MAXIMUM RATE OF FLOW ATTAINABLE AT ANY TIME DURING AN FEV) |
Framingham Cohort | phv00022657 | PEAK EXPIRATORY FLOW RATE - SUMMARY (MAXIMUM RATE OF FLOW ATTAINABLE AT ANY TIME DURING AN FEV) |
Framingham Cohort | phv00022682 | PEAK EXPIRATORY FLOW (LIT./SEC.) - BEST EFFORT |
Genetic Epidemiology of COPD (COPDGene) | phv00169393 | PEF post-bronch |
Genetic Epidemiology of COPD (COPDGene) | phv00169396 | PEF pre-bronch |
Jackson Heart Study (JHS) Cohort | phv00128211 | BEST_PEF - Peak expiratory flow from the best curve: measured in liters |
Jackson Heart Study (JHS) Cohort | phv00128221 | SCND_PEF - Peak expiratory flow from the 2nd best curve: measured in liters per second |
Jackson Heart Study (JHS) Cohort | phv00128231 | THRD_PEF - Peak expiratory flow from the 3rd best curve: measured in liters per second |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087703 | PEAK EXPIRATORY FLOW (ml/sec) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083712 | PEAK EXPIRATORY FLOW (ml/sec) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083477 | PEAK EXPIRATORY FLOW (ml/sec) |
NHLBI Cleveland Family Study (CFS) Candidate Gene Association Resource (CARe) | phv00122580 | Spirometry: peak expiratory flow |
NHLBI Cleveland Family Study (CFS) Candidate Gene Association Resource (CARe) | phv00123042 | Standardized Knudson predictor: PEF |
Mapped dbGaP Studies
Mapping for PX091601_Plateau
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083448 | PLATEAU ACHIEVED |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083683 | PLATEAU ACHIEVED |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087674 | PLATEAU ACHIEVED |
Mapped dbGaP Studies
Mapping for PX091601_Predicted_FEV1
Mapped dbGaP Studies
Mapping for PX091601_Predicted_FEV1/FEV6
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Atherosclerosis Risk in Communities (ARIC) Cohort | phv00095609 | FEV(1) over FEV(6) |
Atherosclerosis Risk in Communities (ARIC) Cohort | phv00095656 | FEV(1) over FEV(6) - BLANK Q17 |
Jackson Heart Study (JHS) Cohort | phv00128215 | BEST_FEV1_FEV6 - FEV1/FEV6 % from best curve |
Jackson Heart Study (JHS) Cohort | phv00128225 | SCND_FEV1_FVE6 - FEV1/FEV6 % from 2nd best curve |
Jackson Heart Study (JHS) Cohort | phv00128235 | THRD_FEV1_FEV6 - FEV1/FEV6 % from 3rd best curve |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083462 | LOWER LIMIT OF NORMAL: FEV1/FEV6 RATIO |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087688 | LOWER LIMIT OF NORMAL: FEV1/FEV6 RATIO |
Mapped dbGaP Studies
Mapping for PX091601_Predicted_FEV1/FVC
Mapped dbGaP Studies
Mapping for PX091601_Predicted_FVC
Mapped dbGaP Studies
Mapping for PX091601_Race
Mapped dbGaP Studies
Mapping for PX091601_Sex
Mapped dbGaP Studies
Mapping for PX091601_Technician_ID
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Jackson Heart Study (JHS) Cohort | phv00128199 | Spirometry technician identifier (3 Digit ID unique to each technician) |
Mapped dbGaP Studies
Mapping for PX091601_Technician_Quality
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Atherosclerosis Risk in Communities (ARIC) Cohort | phv00095627 | Quality Code of Technician (1-5) Q42 |
Atherosclerosis Risk in Communities (ARIC) Cohort | phv00095676 | Quality Code of Technician (1-5) Q42 |
Mapped dbGaP Studies
Mapping for PX091601_Testing_Position
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083453 | TEST POSITION |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083688 | TEST POSITION |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087679 | TEST POSITION |
Mapped dbGaP Studies
Mapping for PX091601_Time
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083479 | TIME TO COMPLETE MANEUVER (sec) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083498 | TIME SPIROMETRY WAS COMPLETED |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083499 | TIME SPIROMETRY WAS COMPLETED: AM/PM |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083714 | TIME TO COMPLETE MANEUVER (sec) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083733 | TIME SPIROMETRY WAS COMPLETED |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083734 | TIME SPIROMETRY WAS COMPLETED: AM/PM |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087705 | TIME TO COMPLETE MANEUVER (sec) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087724 | TIME SPIROMETRY WAS COMPLETED |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087725 | TIME SPIROMETRY WAS COMPLETED: AM/PM |
Mapped dbGaP Studies
Mapping for PX091601_Time_To_PEF
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083480 | TIME TO PEAK EXPIRATORY FLOW (sec) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00083715 | TIME TO PEAK EXPIRATORY FLOW (sec) |
Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | phv00087706 | TIME TO PEAK EXPIRATORY FLOW (sec) |
Mapped dbGaP Studies
Mapping for PX091601_VC
dbGAP Study | dbGAP Variable | dbGAP Variable Description |
---|---|---|
Framingham Cohort | phv00000753 | LUNG FUNCTION: VITAL CAPACITY, ACTUAL, EXAM 5 |
Framingham Cohort | phv00000832 | LUNG FUNCTION: VITAL CAPACITY, EXAM 6 |
Mapped dbGaP Studies
Mapping for PX091601_Weight
View Image
Cite This Protocol
To cite this protocol, copy & paste the text below: